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The interactions between cancer cells and the surrounding host
stromal tissue play a critical role in tumor progression and metas-
tasis, but the molecular nature of this relationship remains largely
uncharacterized. Furthermore, although genetic changes of neo-
plastic cells in tumors contribute significantly to tumor progres-
sion, it is not known whether similar changes occur in the adjacent
host stromal microenvironment and whether they contribute to or
inhibit tumorigenesis. To address this question in an unbiased and
genome-wide manner, we applied high-resolution DNA copy num-
ber analysis to murine stromal DNA isolated from human xenograft
tumors that were formed in immunodeficient mice. We show that
numerous amplifications and deletions are found within the host
stromal microenvironment, suggesting that alterations in host
DNA copy number can occur and may play a significant role in
modifying tumor–stromal interactions.
cancer  stroma  microarray
I t has long been understood that tumors are complex tissues.Genetically aberrant ‘‘cancer cells,’’ the ultimate cause of the
tumor, are only one component of most epithelial tumors; other
‘‘stromal’’ components include cells of mesenchymal origin that
have repeatedly been implicated as potential contributors to the
growth of tumors (1, 2). Tumors frequently also contain many
kinds of inflammatory cells, suggesting a connection between
tumor growth and inflammation (3). Furthermore, the similarity
between the cell populations and activities associated with
normal wound healing and those found in tumors has often been
noted (4, 5). In their influential review, Hanahan and Weinberg
emphasize the possibility that stromal contributions may be vital
to the growth of tumors, and go so far as to suggest that ‘‘. . . in
some tumors, these cooperating cells may eventually depart from
normalcy, co-evolving with their malignant neighbors to sustain
the growth of the latter’’ (1).
Genome-scale comprehensive gene expression studies of solid
tumors have served to illustrate in striking detail the complexity
of tumors and the diversity of nonepithelial cell types they
contain. The earliest studies noted that gene expression profiles
characteristic of stromal and inflammatory cells are usually
detected, as are expression signatures previously associated with
wound healing and angiogenesis (4, 6, 7). These and subsequent
studies of many different tumor types provided a mass of
detailed information, leading to three general observations.
First, each anatomical type of cancer is associated with recog-
nizable expression pattern usually closely related to the pattern
seen in normal tissues; some types (e.g., breast cancer) are
classifiable into a small family of ‘‘subtypes’’ (6, 8, 9). Second,
within a cancer ‘‘subtype,’’ the tumors of each individual nev-
ertheless remain distinguishable by differences in gene expres-
sion pattern. These patterns are the sum of gene expression in
the genetically deranged and the stromal cells comprising the
tumor. Third, the expression profiles of distant metastases tend
to be even more similar to those of the primary tumor than
primary tumors of the same subtype are to each other (breast,
refs. 6 and 10; lung, ref. 7; gastric, ref. 11).
Thus, even distant metastases, presumably founded by a single
migrant cancer cell, somehow become organized like the pri-
mary tumors, acquiring populations of stromal and inflamma-
tory cells very similar to those found in the parent primary. This
implies that the genetically deranged cancer cells in both the
metastasis and the primary tumor must initiate and benefit from
a complex choreography of mutual signaling and support. The
detailed expression pattern appears to be characteristic, possibly
even unique, for each independently arising cancer cell; the
general pattern is characteristic of the particular cancer subtype.
Particularly interesting in this context was the finding by Chen et
al. (11) that, in the case of hepatocellular carcinoma, where an
individual patient might have more than one independently
arising tumor as well as metastases of some of them, only the
clonally related tumors (on the basis of DNA changes) had
similar expression profiles.
Here we describe the results of an experiment designed to
address specifically the possibility that the stromal components
are involved in some kind of ‘‘coevolution’’ with the tumor, by
looking directly for alterations in the genomic DNA of stromal
cells during the establishment of human tumors that result from
the introduction of clones of malignant human tumor cell lines
into nude mice. This cross-species design provided a secure way
to distinguish the genetically human cancer cells from the
putatively coevolving stromal helper cells. Tumors that arise in
this system necessarily have stromal components derived from
the mouse, even though the malignant founder cells are human.
Any changes in stromal cell genomes would be changes in the
mouse genome, and not the human genome.
We used representational oligonucleotide microarray analysis
(ROMA), which has proven to be both sensitive and reliable,
enabling the detection of copy number changes ranging from a
few tens of kilobases to entire chromosome arms (12–14).
Briefly, ROMA’s sensitivity is derived from its reduction of the
complexity of the test and reference genomes analyzed (3% of
the original genome) by making BglII genomic representations,
consisting of small restriction fragments, between 200 and 1,200
base pairs. The BglII restriction fragments are then amplified by
adaptor-mediated PCR, fluorescently labeled and the test and
reference samples are hybridized to custom fabricated microar-
rays containing oligonucleotide probes to BglII fragments de-
signed in silico from the mouse genome sequence assembly to be
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complementary with these fragments. Putative changes detected
by ROMA were then confirmed by using quantitative real-time
PCR (12–14).
Below, we show evidence that amplifications and deletions of
mouse genes of potential biological interest were detected in
these xenograft tumors. The detection of amplifications and
deletions in the stroma indicates the presence of clones of mutant
host cells, and strongly suggests that such cells have been selected
for proliferation in the course of the establishment of the tumors,
a process that takes between 30 and 150 days from the injection
of the human cells.
Results
Detection of Copy Number Alterations in the Genomes of Mouse
Stromal Cells in Human Xenograft Tumors. We reasoned that if
genetically aberrant cancer cells coevolve with the stromal cell
types that are found in human tumors, then malignant human
epithelial cells that establish a complex xenograft tumor that
contains stromal participants in a nude mouse might involve the
mouse stroma in a similar process. Therefore, we produced a
variety of human xenograft tumors in nude mice and examined
the genomes of mouse stromal cells from these tumors for DNA
copy number changes.
Fig. 1 gives an overview of the experimental system, with
additional details available in Materials and Methods and sup-
porting information (SI) Figs. 3 and 4. Human tumor cell lines
of various origins (HCT-15, colorectal carcinoma; MDA-MB-
231, breast adenocarcinoma; MDA-MB-435s, breast carcinoma)
were injected s.c. or i.p. into female NCR nu/nu mice (Fig. 1a).
Tumors developed 30–150 days later, and the gross tumors were
dissected (Fig. 1b). The xenograft tumors were then subjected to
a FACS analysis wherein mouse stromal cell and human cancer
cell nuclei were separated based on DNA content (Fig. 1c). We
then used ROMA to survey the DNA copy number of the
isolated mouse stromal component from the xenograft tumors
(Fig. 1d). Signal noise due to sample degradation (SI Fig. 4) was
overcome through the comparison of stromal nuclei from one
xenograft tumor with the stromal nuclei of a second xenograft
tumor caused by the same human tumor cell line. ROMA
comparison of tail DNA from the mice used in the stromal
analysis was then used to account for any genetic differences
between these outbred individual mice (14). Thus, the copy
number alterations changes reported here are necessarily stro-
mal differences between two tumors. It is important to note that
any consistent changes in the stroma of two tumors would be
normalized out, and therefore not observed using our analysis.
Identification of a deletion in Ighg (SI Fig. 5b) in the stroma of
several tumors (BOT0029, BOT0031) caused by the human
MDA-MB-435s breast carcinoma cell line, presumably the result
of somatic hypermutation and/or V(D)J recombination of the Ig
locus (15, 16) within an inflammatory component of the stroma,
provided early validation of our method.
The ROMA survey identified 38 candidate copy number
alterations in the stroma associated with seven tumors. Fig. 2
presents array data for six copy number alterations (one ampli-
fication and five deletions) contained within the genes EphA4
(Fig. 2 a and b), Ubadc1 (Fig. 2c), Ywhaq and Adam17 (Fig. 2d),
Opcml (Fig. 2e), and Hrnr (Fig. 2f ). ROMA array data for
additional DNA copy number alterations is available in SI Fig.
5. To provide some measure of validation of these and the
remaining ROMA predictions, we applied quantitative PCR
(qPCR) to measure the DNA copy number of the individual
genes encompassed by the array data. Additionally, to delineate
the boundaries of candidate amplifications and deletions, we also
used qPCR to determine the copy number of genes flanking
several of these predictions (SI Table 2).
Alterations in copy number were widely distributed through-
out the genome (Table 1). Significantly, the same genes were not
altered in each tumor produced by a given human cancer cell
line. If indeed there is coevolution, there must be more than one
kind of successful stromal evolutionary path. It is also worth
noting that we found changes of such a magnitude that a large
number of stromal cells in each tumormust have shared the same
amplification and deletion, suggesting strongly a common clonal
origin that then was highly selected during the development of
the xenograft tumor. Finally, it is important to note that the
DNA copy number of the human homologues of the genes
altered in the host stroma are not altered in the parental human
tumors used in this study (data not shown).
In sum, 17 alterations in DNA copy number, constituting a
nonredundant set of 15 unique genes, observed by ROMA analysis
Fig. 1. Isolation of stromal nuclei from human xenograft tumors in NCR
nu/nu mice. (a) Human tumor cell lines of various origins (HCT-15, MDA-MB-
231, MDA-MB-435s) were injected s.c. or i.p. into NCR nu/nu mice. (b) Xeno-
graft tumors developed 30–150 days later, and the gross tumors were dis-
sected. (c) The xenograft tumors were then subjected to FACS analysis, and the
mouse stroma and human tumor nuclei were separated based on DNA con-
tent. (d) ROMA analysis was then performed on isolated stromal material.
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were unambiguously confirmed by direct and flanking qPCR
analysis (Table 1 and SI Table 2). Two of these alterations in copy
number were amplifications, and 15 were deletions (Table 1).
Individual Genes Altered in DNA Copy Number in Tumor Stroma. A
summary is provided of some of the amplification and deletion
events whose known biology is of particular interest with respect
to carcinogenesis or cancer progression (see SI Text). A complete
list of all of the PCR-confirmed events is found in Table 1.
The single most notable event occurred in the stroma of a
xenograft tumor (BOT0011) caused by the human colorectal
carcinoma cell line HCT-15, which contained a 2.8-fold amplifica-
tion of the gene encoding EphA4 (Fig. 2a and Table 1). Interest-
ingly, the stroma of a second xenograft tumor (BOT0018) caused
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Fig. 2. Alterations in stromal DNA copy number identified by ROMA. (a) Amplification in Epha4. (b) Deletion in Epha4. (c) Deletion in Ubadc1. (d) Deletion in
Ywhaq and Adam17. (e) Deletion in Opcml. ( f) Deletion in Hrnr. Copy number profile of stroma from tumor (blue) and normal reference DNA (orange) are
indicated. Probe ratios are plotted on a log10 scale.
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by the human breast carcinoma cell line MDA-MB-435s contained
a 0.43-fold deletion in EphA4 (Fig. 2a and Table 1). In the ROMA
survey, this amplification and deletion were both identified as
single-probe events, and based on PCR, the nearest unamplified
probes were 31.22 kb apart (Table 1). EphA4 is a receptor tyrosine
kinase that belongs to a large family of Ephrin receptors. Although
primarily involved in mediating developmental events directed by
Ephrin (17), particularly in the nervous system, many studies have
indicated a direct role for the ephrins and their receptors in tumor
progression and angiogenesis (18). Increased expression of Ephrins
and their receptors have been correlated with survival and invasive
capacity of colorectal and ovarian cancers (19–21). Additionally,
EphA2 and EphB2 have emerged as attractive drug targets for
cancer therapy (22, 23). That EphA4 was observed as both ampli-
fication and deletion in the stroma caused by two different cell lines
may be related to differences in the parental tumor cell lines as well
as the anatomical location of the xenograft tumors (s.c. versus i.p.).
Discussion
The data summarized above and in Table 1 show that there are
occasional DNA copy number changes in stromal cells of
xenograft tumors in nudemice caused by the introduction of cells
from cloned human cancer cell lines. The DNA copy number
changes are widely dispersed through the mouse genome and
include both amplifications and deletions. Genes within the
generally quite short regions of DNA that are altered (average
length of 497.6 kb) include several whose biology (e.g., EphA4
and Adam17) is immediately interesting with respect to their
potential roles in cancer. A few alterations appear in more than
one independent tumor (e.g., Hornerin, Ubadc1, and EphA4)
and in two cases, the causative cell lines were different.
There are several features to note about our detection of DNA
alterations in tumor stromal cells.
1. Our experimental design allowed us to separate cleanly
stromal cells from the causative cancer cells. There was no
indication in the FACS-sorting step of possible mouse–
human hybrid nuclei (24, 25), nor was there any human
genetic material detected in the DNA from the isolated
mouse nuclei (SI Fig. 3). The changes we detected are not
present in the parental human tumors (data not shown).
2. Our detection of any changes at all (especially the deletions)
implies that there may indeed be a clonal selection process
Table 1. Alterations in stromal DNA copy number validated by qPCR
Gene symbol(s) Gene name(s)
Change
in copy
number
Relative copy
number (2Ct) Band
Deletion
amplicon
size, kb
Sample
name
Tumor
type
Name of
xenograft
tumor
Adamdec1 ADAM-like (decysin 1) Loss 0.42 14D1 256.56 BOT0026 Breast MDA-MB-231
EphA4 Eph receptor A4 Gain 2.84 1qC4 31.22 BOT0011 Colon HCT-15
EphA4 Eph receptor A4 Loss 0.43 1qC4 31.22 BOT0018 Breast MDA-MB-435s
Hrnr Hornerin Loss 0.17 3qF2.1 6.89 BOT0020 Colon HCT-15
Hrnr Hornerin Loss 0.40 3qF2.1 6.89 BOT0028 Breast MDA-MB-435s
Ighg Immunoglobulin heavy chain
(gamma polypeptide)
Loss 0.29 12qF1 553.54 BOT0029 Breast MDA-MB-435s
Ighg Immunoglobulin heavy chain
(gamma polypeptide)
Loss 0.21 12qF1 553.54 BOT0031 Breast MDA-MB-435s
Kcnd2 Potassium voltage-gated channel,
Shal-related family, member 2
(Kv4.2)
Gain 2.40 6qA2 69.48 BOT0028 Breast MDA-MB-435s
Mup1; Mup2 Major urinary protein 1; Major
urinary protein 2
Loss 0.26, 0.26 4qB3 860.02 BOT0029 Breast MDA-MB-435s
Mup1; Mup2 Major urinary protein 1; Major
urinary protein 2
Loss 0.10, 0.14 4qB3 860.02 BOT0031 Breast MDA-MB-435s
Opcml Opioid binding proteincell
adhesion molecule-like
Loss 0.16 9qA4 672.87 BOT0031 Breast MDA-MB-435s
Rabgap1 RAB GTPase activating protein 1 Loss 0.28 2qB 20.77 BOT0028 Breast MDA-MB-435s
Ubadc1 Ubiquitin associated domain
containing 1 (putative
glialblastoma cell
differentiation-related)
Loss 0.37 2qA3 16.13 BOT0028 Breast MDA-MB-435s
Ubadc1 Ubiquitin associated domain
containing 1 (putative
glialblastoma cell
differentiation-related)
Loss 0.14 2qA3 16.13 BOT0029 Breast MDA-MB-435s
Ubadc1 Ubiquitin associated domain
containing 1 (putative
glialblastoma cell
differentiation-related)
Loss 0.18 2qA3 16.13 BOT0031 Breast MDA-MB-435s
V2r14; V2r15; V2r4 Vomeronasal 2, receptor, 14;
Vomeronasal 2, receptor, 15;
Vomeronasal 2, receptor, 4
Loss 0.43, 0.43, 0.06 7qA1 1769.45 BOT0031 Breast MDA-MB-435s
Ywhaq; Adam17 Tyrosine 3-monooxygenase
tryptophan 5-monooxygenase
activation protein, theta
polypeptide; Disintegrin and
metallopeptidase domain 17
Loss 0.06, 0.06 12qA1.2–1.3 2718.49 BOT0020 Colon HCT-15
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involved in the establishment and progression of the kind of
xenograft tumors we studied. Heretofore, there was no direct
reason to believe that stromal cells would show a high degree
of apparent clonality.
3. The observation that the same-cell human cell line causes
tumors that show different stromal cell DNA alterations
suggests that there must be several effective paths for the
mouse cells to evolve and be selected to become tumor
stroma.
Relatively little is known in detail about the biological or
molecular basis for tumor–cell interactions with the stroma,
although there are very many suggestive studies implicating each
of a legion of growth factors, signaling molecules, and extracel-
lular matrix components. Current knowledge of these interac-
tions is based on studies using coculture systems, reconstitution
experiments, histological classification and subsequent micro-
dissection, or subtractive bioinformatics (26–29). Many of these
experiments are complicated by difficulties in separating tumor
cells from stromal cells, on the one hand, and in defining the
cellular source(s) of the many growth factors and signaling
molecules that are detected in tumors.
Establishment of the role of angiogenesis in tumor progression
stands as a notable exception in which these difficulties were
overcome. The stroma has been shown to be a significant source
of VEGF, which stimulates endothelial cells to proliferate and
migrate, resulting in the formation of the tumor-associated
vasculature (30), leading to the emergence of effective therapies
based on blocking this activity (31). The paracrine relationship
between the tumor and stroma during tumor angiogenesis has
also been convincingly demonstrated by the tumor-derived
PDGF-mediated recruitment of stromal fibroblasts to the neo-
vasculature of primary tumor (32, 33).
Various studies have demonstrated alterations in gene expres-
sion, loss of heterozygosity, and epigenetic changes in the stroma
of human cancers (29, 34–41). We did not observe any of these
as DNA copy number changes; instead, we found changes in
genes, some of whose connection to cancer was previously
documented, and some where the connection was just plausible.
We believe that the important result here is that this kind of
analysis can lead to more direct investigation of genes, because
there is evidence that they are, indeed, under selection during
the establishment and/or development of complex tumor tissues.
Implications of an Altered Stromal Genome
The causative role of host DNA copy number variation during
cancer is an interesting question. It is plausible that the DNA
copy number alterations are the result of selective pressures
placed on the stroma by the tumor to foster a pro-oncogenic
microenvironment. Alternatively, they may represent host se-
lection for mutant stromal cells recruited to suppress tumor
progression. Finally, it is possible that our findings are incidental
and that during the process of stromal proliferation, the response
is often clonal, and we are merely detecting preexisting somatic
mutation by our sensitive methods.
This study suggests that a substantial portion of the alterations
observed in both DNA copy number and gene expression seen
in clinical human tumors may be affected by genomic changes in
the tumor-associated stromal tissue. It will be increasingly
important in the future to distinguish which features of the
genomic profiles (DNA copy number or gene expression) are
due to stroma and which are due to primary epithelial cells that
caused the cancer. Although our analysis is able to distinguish
unambiguously between the tumor and host genomes in a mouse
xenograft model, understanding the extent to which genomic
alterations occur in the human stroma associated with human
tumors may prove to be challenging. However, in favorable cases,
where the ploidy of the tumor vastly differs from normal, we can
perform similar studies to the ones just described, cleanly
separating human tumor and stromal nuclei.
The finding that significant DNA copy number alterations
occur in the nontumor stromal tissue at sites of tumor growth has
numerous implications. The accumulation of stromal mutations
within the primary tumormay provide amechanism of resistance
to antiangiogenic and host-targeted therapies (31). These data
underscore the opportunity of attacking cancer-specific activi-
ties of stromal tissue as well as those of the primary tumor (42).
Materials and Methods
Cell Culture and Experimental Tumors.HumanHCT-15,MDA-MB-
231, and MDA-MB-435s tumor cell lines were cultured in
DMEM supplemented with 15% FBS, penicillin/streptomycin,
and L-glutamine. For injection into experimental animals, cells
were grown to 70% confluence, harvested by trypsinization,
washed in PBS, and diluted in PBS at a concentration of 1 107
cells per ml. Cell aliquots were kept on ice until injection.
Eight-week-old femaleNCRnu/numice (Taconic,Germantown,
NY) were injected with a 26-gauge needle either i.p. or s.c. in the
hind flank with 106 cells. Mice were monitored daily for morbidity
and killed by cervical dislocation either when the mouse became
moribund or when tumors reached a diameter of 1 cm. Tumors
were harvested aseptically and immediately frozen in liquid nitro-
gen for archival storage or fixed in 4% buffered formalin for
histological analysis. All animal studies were conducted in accor-
dance with the Institutional Animal Care and Use Committees of
Princeton University and Cold Spring Harbor Laboratory.
Isolation of Stromal Nuclei.Mouse stromal nuclei are isolated from
tumor samples by finely mincing grossly dissected tumors in a
Petri dish in 0.5–1.0 ml of NST-DAPI buffer [800 ml of NST (146
mM NaCl/10 mM Tris base, pH 7.8/1 mM CaCl2/21 mM MgCl2/
0.05% BSA/0.2% Nonidet P-40], 200 ml of 106 mM MgCl2, 10
mg of DAPI, and 0.1% boiled RNase A using two no. 11 scalpels
in a cross-hatching motion. Minced tissue is then incubated on
ice for 15 min. Before flow cytometric analysis, samples were
filtered through 37-m plastic mesh. Nuclei were sorted with a
Becton Dickinson (Franklin Lakes, NJ) FACS DiVa Flow
Cytometer and Cell Sorter. Skin samples from non-tumor-
implanted mice and normal human subjects were prepared as
above and used as reference samples for calibration of FACS
collection gates to differentially sort mouse and human nuclei
based onDNA content (2.5 vs. 2.85 Gb; see also SI Fig. 3). Sorted
stromal nuclei yielded a collection profile identical to that of
normal mouse skin nuclei; sorted human tumor nuclei yielded a
collection profile identical to that of the parental human tumor
cell line.
DNA Digestion, Labeling, and Microarray Hybridization.Digestion of
genomic DNA with BglII, labeling, and hybridization to 85K
oligonucleotide microarrays (NimbleGen Systems, Madison,
WI) were performed as described (13, 14). Briefly, the com-
plexity of the isolated stromal DNAwas reduced bymaking BglII
genomic representations, consisting of small (200–1,200 bp)
fragments amplified by adaptor-mediated PCR. Stromal DNA
samples and matched reference DNA were then labeled differ-
entially with Cy5-dCTP or Cy3-dCTP using Amersham Phar-
macia (Piscataway, NJ) Megaprime labeling kit, and hybridized
in comparison with each other. AnAxonGenePix 4000B scanner
was used to scan processed arrays, and GenePix Pro 4.0 software
was used for quantification of intensity for the arrays.
ROMA Data Analysis. Array data were imported into S-PLUS for
further analysis. Data were normalized by using an intensity-
based Lowess curve-fitting algorithm (43). Log ratio values were
averaged from color reversal experiments. Early iterations of
ROMA analysis of mouse stromal nuclei using matched tail
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DNA as reference were hampered by significant background
noise, likely the result of the early stages of apoptosis in the
xenograft tumor and stromal DNA degradation (SI Fig. 4a). This
obstacle was overcome by performing the ROMA analysis in two
stages: (i) Comparison of stromal nuclei from one xenograft
tumor with the stromal nuclei of a second xenograft tumor; both
xenograft tumors were caused by the same human tumor cell line
and thus shared the same pattern of DNA degradation. This step
significantly reduced background noise and allowed for the
identification of DNA copy number changes in stromal DNA. (ii)
Comparison of tail DNA from the mice used in the stromal
analysis. This stage accounted for any genetic differences be-
tween these outbred individual mice, and facilitated the isolation
of bona fideDNA copy number changes in the stroma from other
genetic differences such as single-nucleotide or copy number
polymorphisms (14). Additional details are available in SI Fig. 4.
Quantitative Real-Time PCR. qPCR primers and dual-labeled flu-
orogenic probes used to validate candidate copy number alter-
ations were designed in silico from the mouse genome, NCBI
Build 33, and manufactured by Sigma-Proligo (Woodlands, TX)
or Integrated DNA Technologies (Coralville, IA). Primer/probe
sequences are available in SI Table 3. DNA copy number was
quantified by using the Applied Biosystems 7900 sequence
detection system (Applied Biosystems, Foster City, CA), and the
data were analyzed with SDS 2.1 software (Applied Biosystems)
using standard protocols.
Candidate copy number alterations based on 1–2 probe events
in ROMA (e.g., EphA4) were validated by using qPCR probes
to three distinct regions of the candidate gene. Probes were
designed to: (i) the BglII fragments producing the probe event
in ROMA, (ii) regions proximal to the BglII fragments, but still
within the candidate gene, and (iii) genes directly f lanking the
candidate gene. Large candidate copy number alterations (10
probe events, e.g., Adam17) were validated by using qPCR
probes to regions within the ROMA prediction, but not specif-
ically to the BglII fragments.
The relative gene copy numbers were derived by using the
formula 2Ct, where Ct is the difference in amplification cycles
required to detect amplification product from equal starting
concentrations of matched reference tail or skin genomic DNA
as compared with genomic DNA from mouse stromal nuclei
isolated from gross dissected xenograft tumors (44). -Actin was
used as a reference probe for normalization. PCRs were per-
formed in quadruplicate, and copy number alterations were
scored as validated if 2Ct (relative copy number) was 1.5
(gain) or 0.5 (loss) with CV 15% of mean 2Ct.
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